2,134 Shares in Abrdn Life Sciences Investors (NYSE:HQL) Acquired by BankPlus Trust Department

BankPlus Trust Department purchased a new position in Abrdn Life Sciences Investors (NYSE:HQL) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,134 shares of the company’s stock, valued at approximately $28,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Ashton Thomas Securities LLC bought a new position in shares of Abrdn Life Sciences Investors in the 3rd quarter worth $148,000. Kingswood Wealth Advisors LLC acquired a new position in Abrdn Life Sciences Investors during the fourth quarter worth $160,000. Kapstone Financial Advisors LLC bought a new position in shares of Abrdn Life Sciences Investors in the third quarter valued at $177,000. Sanctuary Advisors LLC lifted its stake in shares of Abrdn Life Sciences Investors by 11.4% in the third quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company’s stock valued at $183,000 after buying an additional 1,355 shares in the last quarter. Finally, Stephens Inc. AR grew its holdings in shares of Abrdn Life Sciences Investors by 7.6% during the third quarter. Stephens Inc. AR now owns 12,707 shares of the company’s stock valued at $192,000 after buying an additional 896 shares during the last quarter. Institutional investors and hedge funds own 32.21% of the company’s stock.

Insider Activity

In other news, major shareholder Saba Capital Management, L.P. sold 15,143 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $14.27, for a total value of $216,090.61. Following the completion of the sale, the insider now owns 3,381,371 shares in the company, valued at $48,252,164.17. This represents a 0.45 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold 108,186 shares of company stock worth $1,508,866 over the last 90 days. 10.06% of the stock is currently owned by corporate insiders.

Abrdn Life Sciences Investors Stock Performance

HQL opened at $13.53 on Wednesday. Abrdn Life Sciences Investors has a fifty-two week low of $12.76 and a fifty-two week high of $15.90. The company’s 50-day moving average is $13.73 and its 200 day moving average is $14.45.

Abrdn Life Sciences Investors Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Friday, February 21st will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 13.89%. The ex-dividend date is Friday, February 21st.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.